Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2021 Feb 10;20(4):676–690. doi: 10.1158/1535-7163.MCT-20-0663

Figure 3. Concurrent PP2A-activating drug and FLT3 inhibitor treatment increases c-Myc and Pim-1 ubiquitination and proteasomal degradation.

Figure 3.

Ba/F3-ITD (A) and MV4-11 (B) cells pre-treated with 100 μg/ml cycloheximide (CHX) to inhibit new protein translation, with or without addition of the proteasome inhibitor MG-132 (20 μM), were treated with 1 nM quizartinib and/or 2 μM FTY720, or DMSO control, and c-Myc and Pim-1 protein expression was measured by immunoblotting at the time points shown. Results are also shown graphically in Supplementary Figure S4. C. Ba/F3-ITD cell lysates prepared after treatment with 15 nM gilteritinib and 2 μM FTY720, or DMSO control, for 4 hours were pulled down with c-Myc antibody and the immunoprecipitated protein complex was immunoblotted and probed with ubiquitin antibody. D. Ba/F3-ITD cell lysates prepared after treatment with 1nM quizartinib and 2 μM FTY720, or DMSO control, for one hour were pulled down with Pim-1 antibody and the immunoprecipitated protein complex was immunoblotted and probed with ubiquitin antibody.